

# A Convergent Route to 5-(Arylsulfanyl)-6-sulfonamido-3-benzofuranones

Joan Bosch,<sup>\*a</sup> Tomàs Roca,<sup>a</sup> Juan-Lorenzo Catena,<sup>a</sup> Carles Farrerons,<sup>b</sup> Ignasi Miquel<sup>b</sup>

<sup>a</sup> Laboratory of Organic Chemistry, Faculty of Pharmacy, University of Barcelona, E-08028-Barcelona, Spain

Fax +34(93)4021896; E-mail: jbosch@farmacia.far.ub.es


<sup>b</sup> R&D Centre, Labs. SALVAT, S.A., E-08950 Esplugues de Ll., Barcelona, Spain

Received 30 November 1999; revised 31 January 2000

**Abstract:** A procedure for the synthesis of 5-(arylsulfanyl)-2,3-dihydro-6-sulfonamido-3-benzofuranones (**1**) via 5-bromo-3-methoxy-6-nitrobenzofuran (**4**) as a common advanced synthetic intermediate has been developed. The key step consists of a regioselective nucleophilic aromatic substitution of the bromine atom of **4** by an aryl or heteroarylthiol.

**Key words:** nucleophilic aromatic substitutions, heterocycles, benzofuranones, sulfonamides, drugs

5-(Arylsulfanyl)-6-sulfonamidobenzofuran-3-ones **1**<sup>1</sup> have been shown to be selective cyclooxygenase-2 (COX-2) inhibitors,<sup>2</sup> with a high antiinflammatory activity but lacking the undesirable side effects of most traditional nonsteroidal antiinflammatory drugs. There are relatively few methods for the preparation of 3-benzofuranones.<sup>3</sup> Among them, the intramolecular Friedel-Crafts acylation of aryloxyacetic acid derivatives,<sup>4</sup> a useful method for the cyclization of arylpropionic acids (**2**, X = CH<sub>2</sub>) to the corresponding 1-indanones **3**,<sup>5,6</sup> seemed *a priori* to be a suitable method for the preparation of the target 3-benzofuranones **1**. However, negligible or poor yields (0–10%) were obtained in this cyclization for several substrates **2** (X = O), probably due to the easy decarbonylation<sup>7</sup> of the starting aryloxyacetic acid derivatives. Furthermore, this route suffers from an additional synthetic drawback since the arylsulfanyl substituent at position 5 is introduced in the initial steps of the synthesis therefore, for each specific compound **1**, a complete synthetic sequence has to be developed.




Scheme 1

With these difficulties in mind, we have developed a flexible and efficient route to substituted 3-benzofuranones **1** from a common advanced synthetic intermediate, namely 5-bromo-6-nitrobenzofuran (**4**), formed in high yield by a Perkin-type cyclization.<sup>8</sup> The synthesis starts from 4-amino-5-bromo-2-methoxybenzoic acid (**5**)<sup>9</sup> and is outlined in Scheme 2. The crucial step is the nucleophilic aromatic substitution of the bromine atom of **4** by an arylthiol. Subsequent manipulation of the nitro substituent and the enol ether functionality provides a variety of 5-(arylsulfanyl)-6-sulfonamido-3-benzofuranones **1**.

Acid **5** was converted in 61% overall yield to diacid **6** in a five step sequence consisting of diazotization with in situ treatment of the diazonium salt with sodium nitrite in the presence of copper powder, cleavage of the methoxy group, esterification, alkylation of the phenolic hydroxy group with ethyl bromoacetate, and finally alkaline hydrolysis of the resulting diester. The closure of the benzofuran ring was accomplished by treatment of diacid **6** with a mixture of acetic acid, acetic anhydride and sodium acetate to afford 3-acetoxybenzofuran **7** in 71% yield. Acid-catalyzed methanolysis of **7** afforded the key intermediate **4** in 85% yield.

Reaction of **4** with a variety of arylthiols<sup>10</sup> under basic conditions gave the corresponding benzofurans **8** in acceptable to good yields (Scheme 2, Table 1).



**Reagents and conditions:** i) HBF<sub>4</sub>/NaNO<sub>2</sub>, 0°C, then Cu/NaNO<sub>2</sub>, 0°C, 75%; ii) 48% HBr/AcOH/Ac<sub>2</sub>O, Δ, 97%; iii) MeOH/concd H<sub>2</sub>SO<sub>4</sub>, Δ, 85%; iv) BrCH<sub>2</sub>CO<sub>2</sub>Et/K<sub>2</sub>CO<sub>3</sub>/acetone, Δ, 98%; v) 1:1:1 2 N KOH/MeOH/dioxane, r.t., 99%; vi) AcOH/Ac<sub>2</sub>O/AcONa, Δ, 71%; vii) 10:1 MeOH/35% HCl, Δ, 85%; viii) *t*-BuOK/*t*-BuOH, reflux, see Table 1; ix) Fe/NH<sub>4</sub>Cl, 2:1 EtOH/H<sub>2</sub>O, Δ, 82–96%; x) MsCl/Et<sub>3</sub>N/CH<sub>2</sub>Cl<sub>2</sub>, r.t., then 1:10 1 N KOH/THF, r.t., then 1:10 1 N KOH/EtOH, 45°C, 46–68%

Scheme 2

**Table 1** 5-(Arylsulfonyl)benzofurans **8** Prepared from the Common Intermediate **4**

Product	Aryl	Yield (%)
<b>8a</b>	2-thiazolyl	70
<b>8b</b>	4-methyl-2-thiazolyl	50
<b>8c</b>	4-ethyl-2-thiazolyl	60
<b>8d</b>	4-isopropyl-2-thiazolyl	35
<b>8e</b>	1-methyl-2-imidazolyl	52
<b>8f</b>	2-benzothiazolyl	54
<b>8g</b>	3,5-dichloro-2-pyridyl	21
<b>8h</b>	3-(trifluoromethyl)-2-pyridyl	28
<b>8i</b>	5-(trifluoromethyl)-2-pyridyl	30
<b>8j</b>	phenyl	67
<b>8k</b>	3-fluorophenyl	56
<b>8l</b>	4-fluorophenyl	71
<b>8m</b>	2-fluorophenyl	28
<b>8n</b>	3-chlorophenyl	30
<b>8o</b>	4-chlorophenyl	59
<b>8p</b>	3,4-dichlorophenyl	40
<b>8q</b>	2,5-dichlorophenyl	38
<b>8r</b>	2,3-dichlorophenyl	37
<b>8s</b>	2-bromophenyl	18
<b>8t</b>	2-chloro-4-fluorophenyl	56
<b>8u</b>	2-(trifluoromethyl)phenyl	61
<b>8v</b>	4-(trifluoromethyl)phenyl	50
<b>8w</b>	4-(trifluoromethoxy)phenyl	56
<b>8x</b>	2-ethylphenyl	61
<b>8y</b>	2-isopropylphenyl	62

The reaction was general and worked well with diversely substituted phenyl and heteroarylthiols. The enol ether function present in **4** ensures that the  $S_NAr$  process occurs on the carbon atom linked to bromine. In contrast, attempts to displace the bromine atom from the 3-benzofuranone formed by hydrolysis of **4** resulted in the substitution of the nitro group due to the activation exerted by the carbonyl group at the *para* position. Finally, treatment of **8** with iron powder in aqueous ethanol under slightly acidic conditions brought about both reduction of the nitro group and hydrolysis of the enol ether function to give the aminobenzofuranones **9** in 82–96% yield (Scheme 2, Table 2). Sulfonylation with excess methane-sulfonyl chloride, followed by two successive controlled alkaline hydrolytic steps from the resulting *N,N,O*-tris(methylsulfonyl) derivative provided the target 2,3-dihydro-3-benzofuranones **1** in 46–68% yield (Table 3).

In conclusion, an efficient and convergent procedure for the preparation of pharmacologically valuable 5-(arylsulfonyl)-2,3-dihydro-6-sulfonamido-3-benzofuranones **1** via a common advanced intermediate **4** has been developed. Taking advantage of both the activation at C-5 towards the nucleophilic attack and the functionalization of C-6, this intermediate may also provide a synthetic entry to a variety of diversely 5-substituted and 5,6-disubstituted 3-benzofuranones.

Melting points were determined in a capillary tube and are uncorrected. NMR spectra were recorded on a Varian Gemini spectrometer at 300 MHz ( $^1H$ ) and 75 MHz ( $^{13}C$ ). Coupling constants are

expressed in Hertz and signals are quoted as follows: s, singlet; d, doublet; dd, doublet of a doublet; t, triplet; td, triplet of doublets; q, quartet; m, multiplet; br s, broad singlet. Analytical TLC was carried out on Merck silica gel 60 F<sub>254</sub> plates, and the spots were located with UV light. Flash chromatography was carried out on silica gel (silica gel 60, SDS, 0.04–0.06 mm). Drying of organic extracts during the work-up of reactions was performed over anhyd Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvents was accomplished under reduced pressure with a rotatory evaporator. Microanalyses were performed on a Carlo Erba 1106 analyzer by Centro de Investigación y Desarrollo (CSIC), Barcelona.

#### 4-Bromo-2-carboxy-5-nitrophenoxycetic Acid (**6**)

Aq 4 M NaNO<sub>2</sub> solution (140 mL) was added dropwise to an ice-cooled solution of **5**<sup>9</sup> (68.7 g, 279 mmol) in 20% HBF<sub>4</sub> (350 mL). The resulting mixture was stirred at 0 °C for 30 min, and then was added dropwise to a suspension of Cu powder (84.3 g, 1.32 mol) and NaNO<sub>2</sub> (253 g, 3.6 mol) in H<sub>2</sub>O (380 mL). After stirring for 3 h at r.t. the mixture was filtered through Celite and the cake was washed with EtOAc (200 mL) and 2 N HCl (50 mL). The organic phase was successively washed with 2 N HCl (2 × 50 mL) and brine (2 × 75 mL), dried, filtered, and concentrated to give 5-bromo-2-methoxy-4-nitrobenzoic acid as a brown solid; yield: 58.4 g (75%).

A solution of the above acid (36 g, 130 mmol) in AcOH (45 mL), Ac<sub>2</sub>O (40 mL) and 48% HBr (100 mL) was refluxed for 6 h. After addition of cold H<sub>2</sub>O (350 mL), the mixture was extracted with EtOAc (3 × 150 mL). The organic extracts were dried, filtered, and concentrated to give 5-bromo-2-hydroxy-4-nitrobenzoic acid as a brown solid; yield: 33.2 g (97%).

A solution of this acid (33.2 g, 127 mmol) in MeOH (200 mL) and concd H<sub>2</sub>SO<sub>4</sub> (15 mL) was refluxed for 24 h. After cooling to 5 °C, H<sub>2</sub>O (200 mL) was added, and the resulting orange solid was crystallized from MeOH; yield: 29.8 g (85%).

A suspension of the above methyl ester (24.9 g, 90.2 mmol), K<sub>2</sub>CO<sub>3</sub> (18.7 g, 135.3 mmol) and ethyl bromoacetate (12.6 mL, 108.2 mmol) in acetone (400 mL) was refluxed for 12 h. The inorganic salts were filtered off, and the filtrate was concentrated in vacuo. Then, a solution of the crude product in EtOAc (300 mL) was successively washed with saturated Na<sub>2</sub>CO<sub>3</sub> (3 × 100 mL) and brine (200 mL), dried, filtered, and concentrated to give ethyl-4-bromo-2-(methoxycarbonyl)-5-nitrophenoxycetate as an orange solid; yield: 32 g (98%).

A solution of the above diester (32 g, 88.7 mmol) in a 1:1:1 mixture of 2 N KOH/MeOH/dioxane (500 mL) was stirred at r.t. for 18 h. The mixture was acidified with 2 N HCl and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 250 mL). The organic extracts were dried, filtered, and concentrated to give diacid **6** as a brown solid; mp 200–202 °C; yield: 28.1 g (99%).

$^1H$  NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 4.76 (s, 2 H), 7.39 (s, 1 H), 8.23 (s, 1 H).

$^{13}C$  NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 66.9, 106.2, 111.5, 125.5, 138.5, 151.9, 156.4, 164.7, 169.6.

Anal. calcd for C<sub>9</sub>H<sub>6</sub>BrNO<sub>7</sub> (320.9): C, 33.96; H, 1.88; N, 4.36. Found: C, 33.65; H, 1.53; N, 4.63.

#### 3-Acetoxy-5-bromo-6-nitrobenzofuran (**7**)

A solution of **6** (28.1 g, 87.6 mmol) and AcONa (11.4 g, 130.7 mmol) in AcOH (20 mL) and Ac<sub>2</sub>O (110 mL) was refluxed for 4 h. After cooling to 5 °C, H<sub>2</sub>O (100 mL) was added, and the brown solid was filtered; mp 109–111 °C; yield: 18.9 g (71%).

$^1H$  NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 2.41 (s, 3 H), 7.92 (s, 1 H), 8.03 (s, 1 H), 8.26 (s, 1 H).

$^{13}C$  NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.6, 108.1, 110.2, 124.3, 125.8, 133.1, 138.7, 146.4, 149.4, 166.8.

Anal. calcd for  $C_{10}H_6BrNO_5$  (300.1): C, 40.02; H, 2.01; N, 4.67. Found: C, 39.75; H, 2.39; N, 4.30.

#### 5-Bromo-3-methoxy-6-nitrobenzofuran (4)

A solution of **7** (38 g, 126.6 mmol) in MeOH (250 mL) and 35% HCl (25 mL) was refluxed for 6 h. The MeOH was evaporated,  $H_2O$  (100 mL) was added, and the orange precipitate was collected by filtration. Yield: 29.3 g (85%). An analytical sample was crystallized from hexane/ $CH_2Cl_2$  (3:1), mp 160–161 °C.

$^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  = 3.91 (s, 3 H), 7.46 (s, 1 H), 7.93 (s, 1 H), 7.97 (s, 1 H).

$^{13}C$  NMR (75 MHz,  $CDCl_3$ ):  $\delta$  = 58.5, 107.3, 110.1, 124.6, 126.2, 129.6, 144.1, 150.8, 175.4.

Anal. calcd for  $C_9H_6BrNO_4$  (272.0): C, 39.73; H, 2.22; N, 5.15. Found: C, 40.01; H, 2.40; N, 5.21.

#### 5-(Arylsulfanyl)-3-methoxy-6-nitrobenzofurans **8**; General Procedure

*t*-BuOK (20 mmol) and an appropriate arylthiol<sup>10</sup> (25 mmol) were added to a solution of **4** (10 mmol) in *t*-BuOH (110 mL). After stirring at reflux temperature for 72 h, the solution was concentrated to dryness. The solid residue was dissolved in sat. aq.  $Na_2CO_3$  solution, and the aqueous solution was extracted with EtOAc. The organic extracts were dried, filtered, and concentrated to give the corresponding 5-(arylsulfanyl)benzofurans **8a–y** (Tables 1 and 2), which were purified by flash chromatography (hexane/ $CH_2Cl_2$ ).

#### 6-Amino-5-(arylsulfanyl)-2,3-dihydro-3-benzofuranones **9**; General Procedure

$NH_4Cl$  (3.80 mmol) and Fe powder (17 mmol) were added to a solution of **8a–y** (3.50 mmol) in a 2:1 mixture of EtOH/ $H_2O$  (30 mL).

After stirring at reflux temperature for 4 h, the mixture was filtered and the filtrate was concentrated to dryness. The residue was dissolved in EtOAc, and the organic phase washed with saturated aqueous  $Na_2CO_3$ , dried, filtered, and concentrated to give the corresponding benzofuranones **9a–y** in 82–96% yield (Table 2).

#### 5-(Arylsulfanyl)-2,3-dihydro-6-(methylsulfonamido)-3-benzofuranones **1**; General Procedure

A solution of  $MeSO_2Cl$  (1.0 mL, 13.2 mmol) in  $CH_2Cl_2$  (25 mL) was added dropwise to a solution of **9a–y** (4.0 mmol) and  $Et_3N$  (4.5 mL, 32 mmol) in  $CH_2Cl_2$  (75 mL). The mixture was stirred at r.t. for 3 h, and then was concentrated to dryness. The residue was dissolved in EtOAc (75 mL), and the organic phase was successively washed with 1 N HCl (3  $\times$  50 mL) and brine (200 mL), dried, filtered, and concentrated to give the corresponding crude *N,N,O*-tris(methylsulfonyl) derivative, which was dissolved in a 1:10 mixture of 1 N KOH/THF (90 mL). The resulting solution was stirred at r.t. for 5 h. Then,  $H_2O$  (30 mL) was added, and the mixture was acidified with 2 N HCl and extracted with EtOAc. The organic extract was dried, filtered, and concentrated. A solution of the resulting crude *N,O*-bis(methylsulfonyl) derivative in a 1:10 mixture of 1 N KOH/MeOH (50 mL) was stirred at 45 °C for 1.5 h. Then, cold  $H_2O$  (30 mL) was added, and the mixture was acidified with 2 N HCl and extracted with EtOAc. The organic extract was successively washed with 5% aq.  $NaHCO_3$  solution and brine, dried, filtered, and concentrated to give the target benzofuranones **1** in a 46–68% yield (Table 3).

**Table 2** Spectroscopic Data of Selected Benzofurans **8** and Benzofuranones **9**

Product <sup>a</sup>	$^1H$ NMR (300 MHz, $CDCl_3$ ), $\delta$ , <i>J</i> (Hz)	$^{13}C$ NMR (75 MHz, $CDCl_3$ ), $\delta$
<b>8a</b>	3.84 (s, 3 H), 7.41 (s, 1 H), 7.44 (s, 1 H), 7.55 (d, 1 H, <i>J</i> = 3.4), 7.99 (d, 1 H, <i>J</i> = 3.2), 8.28 (s, 1 H)	58.4, 109.9, 110.1, 120.2, 124.5, 126.8, 127.4, 130.1, 144.5, 144.9, 150.9, 159.8
<b>8b</b>	2.54 (s, 3 H), 3.84 (s, 3 H), 7.11 (s, 1 H), 7.39 (s, 1 H), 7.44 (s, 1 H), 8.25 (s, 1 H)	17.3, 58.4, 109.7, 111.4, 119.3, 119.8, 126.8, 128.1, 130.1, 144.4, 150.7, 155.3, 158.2
<b>8c</b>	1.34 (t, 3 H, <i>J</i> = 7.6), 2.89 (q, 2 H, <i>J</i> = 7.6), 3.84 (s, 3 H), 7.11 (s, 1 H), 7.40 (s, 1 H), 7.44 (s, 1 H), 8.26 (s, 1 H)	13.3, 24.9, 58.3, 109.7, 117.9, 119.6, 126.8, 128.2, 130.1, 144.3, 150.6, 158.1, 161.5
<b>8d</b>	1.36 (d, 6 H, <i>J</i> = 6.9), 3.19 (m, 1 H), 3.84 (s, 3 H), 7.09 (s, 1 H), 7.43 (s, 1 H), 7.44 (s, 1 H), 8.27 (s, 1 H)	22.1, 31.0, 58.3, 109.6, 116.7, 119.4, 126.7, 128.2, 130.0, 144.3, 150.5, 158.1, 166.0
<b>8e</b>	3.67 (s, 3 H), 3.81 (s, 3 H), 6.67 (s, 1 H), 7.21 (s, 1 H), 7.34 (s, 1 H), 7.42 (s, 1 H), 8.33 (s, 1 H)	33.9, 58.3, 110.0, 117.2, 124.5, 127.2, 129.7, 130.3, 131.0, 137.1, 142.8, 144.2, 150.2
<b>9a</b>	4.62 (s, 2 H), 5.40 (br s, 2 H), 6.38 (s, 1 H), 7.20 (d, 1 H, <i>J</i> = 3.2), 7.65 (d, 1 H, <i>J</i> = 3.2), 7.94 (s, 1 H)	75.6, 96.0, 109.2, 112.8, 120.3, 134.8, 143.4, 156.5, 176.5, 195.7
<b>9b</b>	2.39 (s, 3 H), 4.63 (s, 2 H), 5.26 (br s, 2 H), 6.37 (s, 1 H), 6.74 (s, 1 H), 7.95 (s, 1 H)	17.2, 75.6, 96.0, 109.3, 112.9, 114.8, 135.0, 153.9, 156.5, 176.5, 195.7
<b>9c</b>	1.25 (t, 3 H, <i>J</i> = 7.5), 2.73 (q, 2 H, <i>J</i> = 7.5), 4.62 (s, 2 H), 5.43 (br s, 2 H), 6.39 (s, 1 H), 6.74 (s, 1 H), 7.92 (s, 1 H)	13.0, 24.8, 75.5, 95.9, 109.2, 112.6, 113.4, 134.8, 156.6, 160.0, 164.8, 176.3, 195.7
<b>9d</b>	1.27 (d, 6 H, <i>J</i> = 6.8), 3.01 (m, 1 H), 4.62 (s, 2 H), 5.43 (br s, 2 H), 6.38 (s, 1 H), 6.72 (s, 1 H), 7.93 (s, 1 H)	22.0, 30.9, 75.5, 95.9, 109.4, 112.4, 112.7, 134.8, 156.5, 164.5, 164.7, 176.4, 195.7
<b>9e</b>	3.74 (s, 3 H), 4.56 (s, 2 H), 5.80 (br s, 2 H), 6.23 (s, 1 H), 6.97 (s, 1 H), 7.04 (s, 1 H), 7.84 (s, 1 H)	34.1, 75.5, 95.8, 109.9, 111.7, 123.8, 129.1, 132.2, 137.6, 157.5, 175.9, 196.0

<sup>a</sup> All new compounds gave satisfactory elemental analyses: C  $\pm$  0.12, H  $\pm$  0.15, N  $\pm$  0.11.

**Table 3** Characteristic Physical and Spectroscopic Data of Benzofuranones **1**

Product <sup>a</sup>	mp (°C)	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ), $\delta$ , <i>J</i> (Hz)	<sup>13</sup> C NMR (75 MHz, CDCl <sub>3</sub> ), $\delta$ , <i>J</i> (Hz)
<b>1a</b>	171–172	3.10 (s, 3 H), 4.70 (s, 2 H), 7.33 (d, 1 H, <i>J</i> = 3.4), 7.54 (s, 1 H), 7.71 (d, 1 H, <i>J</i> = 3.4), 8.06 (s, 1 H), 8.82 (br s, 1 H)	40.2, 75.8, 102.5, 114.3, 117.3, 121.9, 133.6, 143.7, 147.8, 161.7, 176.1, 196.5
<b>1b</b>	177–178	2.40 (s, 3 H), 3.10 (s, 3 H), 4.70 (s, 2 H), 6.85 (s, 1 H), 7.54 (s, 1 H), 8.05 (s, 1 H), 9.10 (br s, 1 H)	17.1, 40.2, 75.8, 102.5, 114.7, 116.5, 117.2, 133.4, 147.9, 154.3, 160.5, 176.1, 196.6
<b>1c</b>	146–147	1.28 (t, 3 H, <i>J</i> = 7.5), 2.75 (q, 2 H, <i>J</i> = 7.5), 3.10 (s, 3 H), 4.69 (s, 2 H), 6.86 (s, 1 H), 7.53 (s, 1 H), 8.05 (s, 1 H), 9.29 (br s, 1 H)	13.1, 24.8, 40.3, 75.8, 102.8, 115.0, 115.4, 117.2, 133.3, 147.9, 176.0, 196.6
<b>1d</b>	138–139	1.27 (d, 6 H, <i>J</i> = 6.8), 3.03 (m, 1 H), 3.10 (s, 3 H), 4.70 (s, 2 H), 6.86 (s, 1 H), 7.53 (s, 1 H), 8.05 (s, 1 H), 9.49 (br s, 1 H)	22.1, 30.9, 40.4, 75.8, 103.2, 114.5, 115.4, 117.3, 133.1, 148.0, 160.5, 165.1, 176.0, 196.7
<b>1e</b>	– <sup>b</sup>	3.15 (s, 3 H), 3.80 (s, 3 H), 4.66 (s, 2 H), 6.99 (s, 1 H), 7.10 (s, 1 H), 7.51 (s, 1 H), 7.96 (s, 1 H)	34.1, 40.5, 75.7, 104.3, 115.2, 116.9, 123.7, 129.0, 131.5, 138.3, 148.9, 175.7, 197.0
<b>1f</b>	157–158	3.01 (s, 3 H), 4.72 (s, 2 H), 7.32 (td, 1 H, <i>J</i> <sub>1</sub> = 1.5, <i>J</i> <sub>2</sub> = 7.3, <i>J</i> <sub>3</sub> = 7.9), 7.42 (td, 1 H, <i>J</i> <sub>1</sub> = 1.5, <i>J</i> <sub>2</sub> = 7.2, <i>J</i> <sub>3</sub> = 8.2), 7.57 (s, 1 H), 7.70 (d, 1 H, <i>J</i> = 7.8), 7.80 (d, 1 H, <i>J</i> = 7.8), 8.07 (s, 1 H), 8.37 (br s, 2H)	40.2, 75.9, 101.9, 112.1, 117.3, 121.1, 122.1, 125.2, 126.6, 134.4, 135.5, 147.8, 153.3, 164.9, 176.6, 196.3
<b>1g</b>	129–131	3.07 (s, 3 H), 4.69 (s, 2 H), 7.51 (s, 1 H), 7.67 (s, 1 H), 7.79 (s, 1 H), 7.90 (s, 1 H), 8.10 (s, 1 H)	40.0, 75.8, 101.2, 111.5, 117.2, 129.4, 129.6, 134.5, 136.5, 146.2, 148.3, 152.9, 176.1, 196.5
<b>1h</b>	181–183	3.10 (s, 3 H), 4.69 (s, 2 H), 7.25 (dd, 1 H, <i>J</i> <sub>1</sub> = 4.6, <i>J</i> <sub>2</sub> = 7.9), 7.53 (s, 1 H), 7.95 (d, 1 H, <i>J</i> = 8.1), 7.96 (s, 1 H), 8.31 (br s, 1 H), 8.42 (d, 1 H, <i>J</i> = 3.6)	40.0, 75.7, 101.9, 112.7, 117.2, 120.8, 122.9 (q, <i>J</i> = 271.9), 124.9 (q, <i>J</i> = 33.8), 134.5, 135.3 (q, <i>J</i> = 5.2), 148.6, 151.9, 155.7, 176.1, 196.5
<b>1i</b>	171–173	3.12 (s, 3 H), 4.72 (s, 2 H), 7.27 (d, 1 H, <i>J</i> = 9.3), 7.54 (s, 1 H), 7.79 (dd, 1 H, <i>J</i> <sub>1</sub> = 2.1, <i>J</i> <sub>2</sub> = 8.4), 7.91 (s, 1 H), 8.12 (s, 1 H), 8.58 (br s, 1 H)	40.1, 75.8, 101.5, 111.7, 117.3, 121.2, 123.1 (q, <i>J</i> = 270.5), 124.3 (q, <i>J</i> = 32.8), 134.1 (q, <i>J</i> = 3.1), 134.4, 146.7 (q, <i>J</i> = 4.2), 148.1, 161.9, 176.1, 196.4
<b>1j</b>	163–165	2.79 (s, 3 H), 4.68 (s, 2 H), 7.10 (d, 2 H, <i>J</i> = 7.5), 7.23 (m, 3 H), 7.46 (s, 1 H), 8.00 (br s, 2 H)	39.6, 75.7, 101.2, 115.1, 117.1, 127.2, 127.8, 129.5, 133.9, 134.6, 147.1, 175.7, 196.2
<b>1k</b>	140–142	2.94 (s, 3 H), 4.72 (s, 2 H), 6.70 (d, 1 H, <i>J</i> = 7.2), 6.89 (m, 2 H), 7.25 (m, 1 H), 7.49 (s, 1 H), 7.97 (br s, 1 H), 8.01 (s, 1 H)	39.9, 75.7, 101.1, 113.3, 113.9 (d, <i>J</i> = 24), 114.0 (d, <i>J</i> = 20.8), 117.2, 122.6 (d, <i>J</i> = 3.8), 130.9 (d, <i>J</i> = 8.5), 134.4, 137.2 (d, <i>J</i> = 7.4), 147.2, 163.1 (d, <i>J</i> = 248.7), 175.9, 196.4
<b>1l</b>	100–102	2.91 (s, 3 H), 4.71 (s, 2 H), 7.02 (t, 2 H, <i>J</i> = 8.1), 7.14 (dd, 2 H, <i>J</i> <sub>1</sub> = 4.8, <i>J</i> <sub>2</sub> = 8.1), 7.45 (s, 1 H), 8.02 (br s, 2 H)	39.9, 75.7, 101.0, 115.3, 116.7 (d, <i>J</i> = 21), 117.0, 129.5, 130.1 (d, <i>J</i> = 8.2), 133.6, 146.8, 161.9 (d, <i>J</i> = 246.8), 175.6, 196.5
<b>1m</b>	146–148	3.01 (s, 3 H), 4.68 (s, 2 H), 7.09 (m, 3 H), 7.28 (m, 1 H), 7.45 (s, 1 H), 8.00 (s, 1 H), 8.10 (br s, 1 H)	39.8, 75.6, 100.6, 114.1, 116.2 (d, <i>J</i> = 21), 117.0, 121.5 (d, <i>J</i> = 17.5), 125.0, 129.8 (d, <i>J</i> = 7.7), 131.1, 133.9, 147.0, 160.4 (d, <i>J</i> = 244.6), 175.5, 196.4
<b>1n</b>	87–89	2.94 (s, 3 H), 4.73 (s, 2 H), 7.00 (d, 1 H, <i>J</i> = 2.4), 7.19 (m, 3 H), 7.50 (s, 1 H), 7.94 (br s, 1 H), 8.02 (s, 1 H)	39.9, 75.7, 101.1, 113.3, 117.3, 125.2, 126.5, 127.2, 130.5, 134.4, 135.5, 136.7, 147.1, 176.0, 196.4
<b>1o</b>	150–152	2.96 (s, 3 H), 4.73 (s, 2 H), 7.06 (d, 2 H, <i>J</i> = 10.2), 7.27 (d, 2 H, <i>J</i> = 9.5), 7.49 (s, 1 H), 8.00 (br s, 1 H), 8.03 (s, 1 H)	39.9, 75.7, 100.9, 114.1, 117.1, 128.7, 129.6, 133.1, 134.1, 146.9, 175.8, 196.5
<b>1p</b>	141–143	3.01 (s, 3 H), 4.71 (s, 2 H), 6.90 (d, 1 H, <i>J</i> = 8.1), 7.08 (s, 1 H), 7.32 (d, 1 H, <i>J</i> = 8.4), 7.46 (s, 1 H), 7.97 (s, 1 H)	40.1, 75.8, 101.1, 112.8, 117.3, 126.1, 128.2, 131.1, 133.7, 134.4, 134.9, 147.1, 176.0, 196.5
<b>1q</b>	190–192	3.05 (s, 3 H), 4.75 (s, 2 H), 6.52 (d, 1 H, <i>J</i> = 2.4), 7.13 (dd, 1 H, <i>J</i> <sub>1</sub> = 2.4, <i>J</i> <sub>2</sub> = 8.4), 7.34 (d, 1 H, <i>J</i> = 8.4), 7.55 (s, 1 H), 7.87 (br s, 1 H), 8.00 (s, 1 H)	40.1, 75.9, 101.1, 111.6, 117.6, 126.2, 127.7, 130.1, 131.1, 133.6, 134.8, 136.0, 147.3, 176.1, 196.2,
<b>1r</b>	156–158	3.07 (s, 3 H), 4.73 (s, 2 H), 6.48 (dd, 1 H, <i>J</i> <sub>1</sub> = 1.2, <i>J</i> <sub>2</sub> = 7.9), 7.04 (t, 1 H, <i>J</i> <sub>1</sub> = 7.9, <i>J</i> <sub>2</sub> = 8.2), 7.30 (dd, 1 H, <i>J</i> <sub>1</sub> = 1.2, <i>J</i> <sub>2</sub> = 8.2), 7.51 (s, 1 H), 7.95 (br s, 1 H), 7.98 (s, 1 H)	40.2, 75.8, 100.9, 112.1, 117.4, 124.4, 127.7, 128.1, 129.7, 134.0, 134.8, 136.7, 147.4, 175.9, 196.1

Table 3 (continued)

Product <sup>a</sup>	mp (°C)	<sup>1</sup> H NMR (300 MHz, CDCl <sub>3</sub> ), δ, J (Hz)	<sup>13</sup> C NMR (75 MHz, CDCl <sub>3</sub> ), δ, J (Hz)
<b>1s</b>	187–189	2.98 (s, 3 H), 4.71 (s, 2 H), 6.54 (dd, 1 H, $J_1=1.5$ , $J_2=7.8$ ), 7.07 (td, 1 H, $J_1=1.8$ , $J_2=7.3$ , $J_3=7.8$ ), 7.15 (td, 1 H, $J_1=1.5$ , $J_2=7.5$ , $J_3=7.8$ ), 7.50 (s, 1 H), 7.57 (dd, 1 H, $J_1=1.5$ , $J_2=7.8$ ), 7.97 (br s, 1 H), 8.01 (s, 1 H)	40.0, 75.7, 101.1, 113.7, 117.4, 122.0, 127.4, 128.0, 128.2, 133.4, 134.5, 136.0, 147.3, 175.9, 196.4
<b>1t</b>	160–162	3.04 (s, 3 H), 4.71 (s, 2 H), 6.84 (m, 2 H), 7.18 (dd, 1 H, $J_1=2.7$ , $J_2=8.4$ ), 7.47 (s, 1 H), 7.98 (s, 1 H), 8.02 (br s, 1 H)	40.1, 75.7, 100.9, 113.6, 115.3 (d, $J=21.5$ ), 117.3, 117.9 (d, $J=25.2$ ), 129.1, 129.9 (d, $J=8.5$ ), 133.9 (d, $J=10.0$ ), 134.1, 147.1, 161.5 (d, $J=250.2$ ), 175.8, 196.3
<b>1u</b>	172–173	2.93 (s, 3 H), 4.74 (s, 2 H), 6.92 (d, 1 H, $J=9$ ), 7.36 (m, 2 H), 7.50 (s, 1 H), 7.72 (d, 1 H, $J=8.7$ ), 7.96 (br s, 1 H), 8.04 (s, 1 H)	39.9, 75.7, 101.3, 113.4, 117.2, 123.5 (q, $J=327$ ), 127.1 (q, $J=5.4$ ), 127.2, 128.4 (q, $J=36.8$ ), 128.9, 132.5, 134.2, 134.7, 147.2, 176.0, 196.4
<b>1v</b>	130–132	2.93 (s, 3 H), 4.72 (s, 2 H), 7.13 (d, 2 H, $J=7.8$ ), 7.49 (s, 1 H), 7.51 (d, 2 H, $J=7.8$ ), 7.97 (s, 1 H), 8.01 (s, 1 H)	40.1, 75.8, 101.0, 112.4, 117.3, 123.8 (q, $J=270.5$ ), 126.3 (q, $J=3.9$ ), 126.5, 138.9 (q, $J=32.8$ ), 134.6, 139.9, 147.3, 176.0, 196.3
<b>1w</b>	152–153	2.94 (s, 3 H), 4.72 (s, 2 H), 7.14 (s, 2 H), 7.48 (s, 1 H), 8.00 (br s, 1 H), 8.02 (s, 1 H)	39.9, 75.7, 101.0, 114.0, 117.2, 120.2 (q, $J=254.2$ ), 122.1, 128.8, 133.3, 134.2, 147.0, 148.1, 175.8, 196.4
<b>1x</b>	134–136	1.30 (t, 3 H, $J=7.5$ ), 2.82 (s, 3 H), 2.84 (q, 2 H, $J=7.5$ ), 4.70 (s, 2 H), 6.66 (dd, 1 H, $J_1=0.9$ , $J_2=7.9$ ), 7.03 (td, 1 H, $J_1=1.5$ , $J_2=7.8$ , $J_3=7.8$ ), 7.15 (td, 1 H, $J_1=0.9$ , $J_2=7.5$ , $J_3=7.5$ ), 7.23 (dd, 1 H, $J_1=1.5$ , $J_2=7.6$ ), 7.49 (s, 1 H), 7.87 (br s, 1 H), 7.96 (s, 1 H)	14.4, 26.7, 39.6, 75.7, 101.2, 114.9, 117.3, 126.8, 126.9, 127.1, 129.1, 133.2, 133.9, 142.3, 147.0, 175.7, 196.6
<b>1y</b>	188–190	1.31 (d, 6 H, $J=6.9$ ), 2.79 (s, 3 H), 3.46 (m, 1 H), 4.70 (s, 2 H), 6.66 (dd, 1 H, $J_1=0.9$ , $J_2=7.9$ ), 7.01 (td, 1 H, $J_1=1.5$ , $J_2=7.8$ , $J_3=7.8$ ), 7.19 (td, 1 H, $J_1=0.9$ , $J_2=7.5$ , $J_3=7.5$ ), 7.32 (dd, 1 H, $J_1=1.5$ , $J_2=7.6$ ), 7.49 (s, 1 H), 7.85 (br s, 1 H), 7.97 (s, 1 H)	23.2, 30.5, 39.6, 75.7, 101.2, 115.3, 117.3, 126.2, 126.8, 127.0, 129.3, 132.6, 133.8, 147.0, 175.7, 196.6

<sup>a</sup> All new compounds gave satisfactory elemental analyses: C ± 0.37, H ± 0.25, N ± 0.39.<sup>b</sup> Decomposes above 120 °C.

## Acknowledgement

This work was supported by the CICYT (Spain)-European Commission (project 2FD97-0450). Thanks are also due to the Comissionat per Universitats i Recerca (Generalitat de Catalunya) for Grant 1997SGR-00018.

## References

- (a) Farrerons, C.; Bosch, J.; Lagunas, C.; Casadevall, C.; Catena, J.-L.; Montserrat, C. ES Patent 2138902, 2000.  
(b) Schroeder, E.; Lehman, M.; Rufer, C. US Patent 4411910, 1983; *Chem Abstr.* **1983**, 98, 71912.
- For a review on selective COX-2 inhibitors, see: Beuck, M. *Angew. Chem., Int. Ed. Engl.* **1999**, 38, 631.
- (a) Cagniant, P.; Cagniant, D. In *Advances in Heterocyclic Chemistry*, Vol. 18; Katritzky, A. R.; Boulton, A. J., Ed.; Academic Press: London, 1975; pp 373–435.  
(b) Bird, C. W. In *Comprehensive Heterocyclic Chemistry II*, Vol 2; Katritzky, A. R.; Rees, C. W.; Scriven, E. F. V., Ed.; Pergamon: London, 1996; pp 368–375.
- (a) Adams, J.; Garigipati, R.; Sorenson, M.; Schmidt, S.; Brian, W.; Newton, J.; Tyrrel, K.; Garver, E.; Yodis, L.; Chabot, M.; Tzimas, M.; Webb, E.; Breton, J.; Griswold, D. *J. Med. Chem.* **1996**, 39, 5035.  
(b) Metwally, M.; Darwish, Y.; El-Hussini, M.; Amer, F. *J. Indian. Chem. Soc.* **1988**, 65, 54.
- (a) House, H. O.; Hudson, C. B. *J. Org. Chem.* **1970**, 35, 647.  
(b) House, H. O.; McDaniel, W. C. *J. Org. Chem.* **1977**, 42, 2155.
- In our case, Friedel–Crafts cyclization of **2** (X = CH<sub>2</sub>, Ar = 2,4-difluorophenyl) to the corresponding indanone **3**, which has the same substitution pattern as **1**, proceeded in 70% yield.
- For precedents see: Palmer, M.; McVie, G. *J. Chem. Soc. (B)* **1968**, 745.
- Cagniant, P.; Kirsch, G. *C. R. Acad. Sc. Paris* **1976**, Ser. C, 993.
- Commercially available from Deltafarma, Spain.
- 4-Alkyl-2-mercaptotiazoles were prepared as described in the literature: Ritter, J. J.; Sokol, H. *J. Am. Chem. Soc.* **1948**, 70, 3419.

Article Identifier:

1437-210X,E;2000,0,05,0721,0725,ftx,en;P06799SS.pdf